To NASDAQ OMX Copenhagen A/S
Announcement no. 13-13 / Copenhagen, April 30, 2013
On April 17, 2013, Topotarget A/S increased its share capital by 22,500 shares. In accordance with Executive Order no. 657 of June 22, 2012 concerning Issuers' Disclosure Obligations, it is hereby notified that on April 30, 2013, Topotarget A/S had a share capital of nominal DKK 143,317,114, consisting of 143,317,114 shares each of DKK 1 nominal value. Each share of DKK 1 carries one vote, corresponding to a total number of voting rights of 143,317,114.
For further information, please contact:
Topotarget A/S
Anders Vadsholt, CEO: Direct: +45 39178345
About Topotarget
Topotarget (NASDAQ OMX: TOPO) is an international biopharmaceutical company headquartered in Copenhagen, Denmark, dedicated to clinical development and registration of oncology products. In collaboration with Spectrum Pharmaceuticals, Inc., Topotarget focuses on the development of its lead drug candidate, belinostat, which has shown positive results in the treatment of hematological malignancies and solid tumors, obtained by both mono- and combination therapy. For more information, please refer to www.topotarget.com.
Topotarget Safe Harbor Statement
This announcement may contain forward-looking statements, including statements about Topotarget A/S’ expectations to the progression of Topotarget A/S’ clinical pipeline and with respect to cash burn guidance. Such statements are subject to risks and uncertainties of which many are outside the control of Topotarget A/S, and which could cause actual results to differ materially from those described. Topotarget A/S disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by Danish law.
